[{"id":"1181102e-30ce-4b11-b1b5-b1b8daff71ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447612","created_at":"2021-01-18T21:24:05.076Z","updated_at":"2024-07-02T16:36:43.827Z","phase":"Phase 2","brief_title":"Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04447612","lead_sponsor":"The University of Hong Kong","biomarkers":" ALB","pipe":" | ","alterations":" PD-L1 expression","tags":["ALB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2020-06-25"},{"id":"16b0da6f-245d-47b0-a45e-00b6509e57da","acronym":"","url":"https://clinicaltrials.gov/study/NCT00460109","created_at":"2021-01-18T01:38:02.217Z","updated_at":"2024-07-02T16:37:23.304Z","phase":"Phase 2","brief_title":"Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00460109","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ALB","pipe":"","alterations":" ","tags":["ALB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2017-04-18"}]